Jade Carrere
Adult Health · Houma, LANPI 1124403001
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 72.3% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $21,011, more than ten times the $479 reported in 2021. Among adult health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $256.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$17K
- Regeneron Healthcare Solutions, Inc.$4K
- AstraZeneca$1K
- GSK$646
- Boehringer Ingelheim$378
- Mylan Specialty L.p.$232
- plus $212 from 3 others
What the payments were for
- Consulting fees$2,0889%
- Speaking & faculty fees$12,64454%
- Travel & lodging$4,10118%
- Food & beverage$4,51119%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 26 | $16,909 |
| Regeneron Healthcare Solutions, Inc. | 20 | $3,725 |
| AstraZeneca | 17 | $1,277 |
| GSK | 18 | $646 |
| Boehringer Ingelheim | 4 | $378 |
| Mylan Specialty L.p. | 2 | $232 |
| Amgen | 2 | $141 |
| Tactile Systems Technology Inc | 1 | $41 |
| Abiomed | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,378 in reported general payments places this provider in the 95th percentile of 203 adult health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 51 | $738,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 909 | $710,806 |
| Dupixent PenDupilumab | 80 | $319,617 |
| NucalaMepolizumab | 56 | $231,888 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 312 | $212,025 |
| Fasenra PenBenralizumab | 22 | $136,649 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 182 | $98,698 |
| XolairOmalizumab | 21 | $80,885 |
| Breo ElliptaFluticasone/Vilanterol | 183 | $79,743 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 95 | $63,735 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 51 | $21,836 |
| Spiriva RespimatTiotropium Bromide | 40 | $21,467 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $17,732 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $13,937 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 537 | $12,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $646 | $1,127,0371,349 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $378 | $837,142204 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,277 | $251,593431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 adult health providers in Louisiana.
Other adult health in Houma
- Joan SmithBaton Rouge$121K
- Fiona WinterbottomNew Orleans$51K
- Damika HarmonLake Charles$27K
- Deborah SmithBaton Rouge$18K
- Tanisha SmithBaton Rouge$17K
- Eva Marina StaffordBaton Rouge$15K
- Dustin DenicolaBaton Rouge$14K
- Melissa LamaPonchatoula$13K
- Wendy GillBaton Rouge$13K
- Jennifer LeblancBaton Rouge$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.